Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge
Marcha Verheijen
Journal of the Netherlands Society of Toxicology 2024 DOI: 10.61833/jnst.2024.0002 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Psilocybin Depression |
| Keywords | Depression economics Current fluid Psychotherapist Hallucinogen |
| Citations | 1 |
| Key findings | Psilocybin-assisted therapy produces rapid and sustained antidepressant effects in major depressive disorder and treatment-resistant depression, with a favorable safety profile. |
Abstract
Depression, affecting over 264 million people globally, presents significant treatment challenges, often due to the limited efficacy and adverse effects of traditional antidepressants and the accessibility issues associated with psychotherapy. Recent advancements in psychedelic-assisted therapy, particularly using psilocybin, a naturally occurring compound found in “magic mushrooms”, shows promising potential for treating major depressive disorder (MDD) and treatment-resistant depression (TRD). This review explores the historical context, clinical trial outcomes, and the biological mechanisms underlying psilocybin’s effects. Clinical studies from 2016 to 2023 indicate that psilocybin, in combination with psychological support, significantly reduces depressive symptoms, with benefits lasting up to several months after a single dose treatment. The molecular action of psilocybin involves its conversion to psilocin, which interacts with serotonin receptors, notably the 5-HT2A receptor, influencing neurotransmitter systems and promoting anti-inflammatory responses and neuroplasticity. The review also discusses the safety profile of psilocybin, highlighting its low risk for dependency and minimal adverse effects compared to traditional treatments. Finally, the therapeutic advantages of psilocybin over conventional antidepressants are evaluated, emphasizing its rapid and sustained antidepressant effects, which contribute to its potential as a groundbreaking treatment for depression.
Comparable studies
Other narrative reviews on psilocybin for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression | 2021 | Review | |
| Registered clinical studies investigating psychedelic drugs for psychiatric disorders. Registered clinical trials on clinicaltrials.gov evaluating psychedelics for... | 2021 | Review | n = 70 |
| Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review | 2020 | Review | |
| From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders | 2021 | Review |